A combination of epigenetic factors and compounds that have biespec u00edficos as Diana CD33 and CD3 in the treatment of myeloid leukaemia, where the epigenetic factor is selected from the group consisting of inhibitors of histone deacetylase (HDAC), inhibitors of DNA metiltransferas (Dnmt) I, Hydroxyurea, granulocyte colony stimulating factor (g-csf),Inhibitors of Histone demethylase and atra (all trans retinoic acid). A Pharmaceutical composition comprising a compound having at least one as Diana CD33 and epigenetic factor. An epigenetic factor for use in the Improvement and / or treatment of myeloid leukaemia, where the epigenetic factor increases a patient's response to a compound that targets CD33.Use of at least one epigenetic factor to increase the responsiveness of myeloid leukemia in a patient treated with a compound that targets CD33, a method for the treatment of myeloid leukemia.That includes the Administration of at least one epigenetic factor and a compound that targets CD33 to a patient in need thereof and a kit comprising a Pharmaceutical Composition of the present or epigenetic factor of the present and a compound that is biespec u00edfico Diana CD33.Claim 1: a Pharmaceutical composition comprising a compound having at least one as Diana CD33 and epigenetic factor,(a) where the compound that targets CD33 is a Construct comprising a First biespec u00edfico binding domain that binds specifically to CD33 and a Second binding domain that binds specifically to CD3； and (b) at least one selected from the group that is epigenetic factor Consists of inhibitors of histone deacetylase (HDAC), inhibitors of DNA METHYLTRANSFERASe (Dnmt) I,Hydroxyurea, granulocyte colony stimulating factor (g-csf), inhibitors of Histone METHYLTRANSFERASe (HMT) and atra (all trans retinoic acid).Claim 2: the pharmaceutical Composition of claim 1, wherein the at least one epigenetic factor is selected from the Group comprising (a) an inhibitor of histone deacetylase (HDAC) select
